HealthModerna and Merck say melanoma vaccine succeeds in trial

Moderna and Merck say their experimental personalised cancer vaccine succeeded in a late-stage melanoma trial. Although the study is still underway, interim findings showed it met its main goal of reducing recurrence and its secondary goal of preventing the cancer from spreading.